Chemistry and human therapeutics

Our researchers work in chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.

 

Our researchers work in chemistry and biology to better understand the molecular mechanisms of life, ageing, disease and death.
 

Research areas

  • Chemistry (organic, medicinal, biological)

  • Biochemistry (protein-protein interactions, enzymology)

  • Pharmacology (cellular receptors, animal models of physiology and disease)

  • Immunology (innate immunity, T cell modulators)

Research projects

Our facilities & services

Publications (& journals)

Group leader

Prof David Fairlie

Professor David Fairlie

Group Leader, Chemistry and human therapeutics

Head, Chemistry and Structural Biology Division

Investigator, Centre for Inflammation and Disease Research

Investigator, Centre for Pain Research

  +61 7 334 62989
  d.fairlie@imb.uq.edu.au
  UQ Researcher Profile

Our approach

Our chemists study organic, medicinal and biological chemistry, especially using organic synthesis, computer-aided molecular design, and nuclear magnetic resonance spectroscopy to create new chemical structures that interact with or mimic protein surfaces.

We discover new chemical structures, reactions and mechanisms; enzyme inhibitors, agonists and antagonists of protein function; and molecules that mimic the structures and functions of bioactive protein surfaces.

Our biologists study mechanisms of protein and cell activation, signalling pathways, biological processes, disease development and drug action.

We use novel experimental compounds discovered in our group as molecular tools to interrogate the functions of human proteins and cells, and apply some of them to the treatment of animal models of human diseases.

Our interdisciplinary expertise across multiple subdisciplines of chemistry and biology is used to gain insights into chemical and biochemical processes, physiology and disease, and we develop skills in chemistry, biochemistry, pharmacology, immunology, oncology, virology or neurobiology.

We work, in some cases with industry partners, to discover new basic research and apply some of our discoveries to develop experimental treatments for viral or parasitic infections, such as HIV, dengue fever and malaria; inflammatory diseases, such as arthritis, asthma, inflammatory bowel disease and rare immunological disorders; metabolic and cardiovascular disorders linked to obesity and type 2 diabetes; neurodegenerative diseases; and cancers.

Our team
 

  Group Leader

  • Professor David Fairlie

    Division Head & Group Leader, Chemistry and Structural Biology Division
    Professiorial Research Fellow - GL
    Institute for Molecular Bioscience

  Researchers

  Students

  Support staff

Research excellence

$1.3 billion+ commercial investment attracted to IMB research
1454 international collaborators
 
385 original publications in 2020
 
$28M in research funding last calendar year
 
20%+ of patent families at UQ are derived from IMB research
100% of donations go to the cause
 

Help us shape the future
 

 Donate        Learn with us

Stories

  • IMB researchers have made a big step towards improving the way we study immune responses to bacterial infections.
  • Australian researchers are a step closer to understanding immune sensitivities to well-known, and commonly prescribed, medications. Many drugs are successfully used to treat diseases, but can also have harmful side effects. While it has been known that some drugs can unpredictably impact on the functioning of the immune system, our understanding of this process has been unclear.
  • University of Queensland health and medical research projects aimed at improving the nation’s healthcare will benefit from more than $42 million in funding from the National Health and Medical Research Council for 2017.

Pages

Connect with us

           ​